NASDAQ:BIIB
$290.08
(
-0.630%
)
Friday, 27th Jan 2023
Biogen Inc. Stock Price (Quote)
Range | Low Price | High Price | Comment |
---|---|---|---|
30 days | $265.32 | $295.90 | Friday, 27th Jan 2023 BIIB stock ended at $290.08. This is 0.63% less than the trading day before Thursday, 26th Jan 2023. During the day the stock fluctuated 2.05% from a day low at $289.94 to a day high of $295.90. |
90 days | $265.32 | $311.88 | |
52 weeks | $187.16 | $311.88 |
Historical Biogen Inc. prices
Date | Open | High | Low | Close | Volume |
2023-01-27 | $292.36 | $295.90 | $289.94 | $290.08 | 894 084 |
2023-01-26 | $292.34 | $293.01 | $289.67 | $291.92 | 544 881 |
2023-01-25 | $291.44 | $292.79 | $288.37 | $292.34 | 707 408 |
2023-01-24 | $291.93 | $293.34 | $289.33 | $291.88 | 907 854 |
2023-01-23 | $285.97 | $292.32 | $285.52 | $291.93 | 1 538 088 |
2023-01-20 | $282.36 | $286.40 | $280.28 | $285.77 | 1 101 517 |
2023-01-19 | $281.40 | $284.36 | $280.13 | $280.13 | 623 126 |
2023-01-18 | $290.58 | $291.91 | $282.65 | $283.47 | 1 322 300 |
2023-01-17 | $287.32 | $290.13 | $286.33 | $289.59 | 1 167 209 |
2023-01-13 | $286.99 | $289.51 | $285.15 | $288.04 | 1 008 086 |
2023-01-12 | $283.95 | $288.21 | $280.06 | $288.08 | 1 218 000 |
2023-01-11 | $281.85 | $285.33 | $281.24 | $285.03 | 1 386 200 |
2023-01-10 | $276.83 | $283.38 | $275.32 | $281.46 | 1 379 430 |
2023-01-09 | $280.54 | $281.99 | $269.06 | $274.72 | 1 715 870 |
2023-01-06 | $276.01 | $292.59 | $272.44 | $279.25 | 3 723 400 |
2023-01-05 | $269.33 | $272.80 | $265.32 | $271.59 | 1 163 760 |
2023-01-04 | $275.38 | $275.44 | $269.88 | $270.81 | 1 069 889 |
2023-01-03 | $276.73 | $278.00 | $272.39 | $272.63 | 1 084 413 |
2022-12-30 | $274.98 | $277.15 | $272.20 | $276.92 | 638 502 |
2022-12-29 | $274.83 | $279.14 | $274.30 | $276.00 | 592 788 |
2022-12-28 | $275.64 | $276.92 | $272.64 | $274.04 | 508 828 |
2022-12-27 | $279.89 | $279.89 | $273.38 | $274.77 | 638 473 |
2022-12-23 | $280.45 | $280.45 | $276.07 | $279.16 | 624 675 |
2022-12-22 | $283.61 | $283.65 | $278.31 | $280.61 | 946 899 |
2022-12-21 | $288.09 | $288.30 | $284.87 | $286.86 | 797 010 |
2022-12-20 | $284.94 | $288.89 | $283.85 | $287.51 | 873 226 |
2022-12-19 | $284.90 | $285.50 | $281.59 | $284.38 | 863 419 |
2022-12-16 | $280.56 | $285.59 | $279.07 | $284.98 | 3 046 750 |
2022-12-15 | $287.58 | $287.90 | $282.04 | $283.44 | 1 090 243 |
2022-12-14 | $290.15 | $294.18 | $287.15 | $289.05 | 905 267 |
2022-12-13 | $293.75 | $294.69 | $288.14 | $291.24 | 933 285 |
2022-12-12 | $285.00 | $290.86 | $282.57 | $290.59 | 1 067 277 |
2022-12-09 | $289.10 | $292.97 | $285.14 | $285.37 | 982 783 |
2022-12-08 | $291.86 | $292.32 | $286.72 | $289.10 | 1 695 560 |
2022-12-07 | $292.56 | $293.60 | $287.10 | $292.15 | 1 112 808 |
2022-12-06 | $292.22 | $295.07 | $288.53 | $291.47 | 1 036 051 |
2022-12-05 | $299.18 | $299.70 | $290.23 | $292.75 | 1 498 385 |
2022-12-02 | $299.24 | $305.06 | $297.78 | $298.90 | 1 682 653 |
2022-12-01 | $305.51 | $306.28 | $299.17 | $301.85 | 1 927 908 |
2022-11-30 | $306.28 | $311.88 | $301.20 | $305.17 | 4 068 326 |
2022-11-29 | $291.10 | $293.97 | $288.44 | $291.41 | 1 104 148 |
2022-11-28 | $296.03 | $303.11 | $290.31 | $291.90 | 2 068 717 |
2022-11-25 | $304.35 | $307.53 | $302.70 | $305.15 | 470 765 |
2022-11-23 | $307.00 | $307.40 | $302.11 | $303.45 | 997 998 |
2022-11-22 | $302.25 | $307.00 | $301.60 | $306.72 | 869 193 |
2022-11-21 | $304.20 | $305.87 | $300.41 | $302.08 | 631 817 |
2022-11-18 | $303.21 | $304.14 | $299.72 | $301.49 | 492 190 |
2022-11-17 | $297.07 | $302.93 | $296.79 | $301.52 | 636 896 |
2022-11-16 | $300.17 | $303.56 | $299.00 | $300.00 | 529 675 |
2022-11-15 | $300.67 | $303.79 | $297.01 | $299.63 | 942 758 |
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad... BIIB Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.